

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: M. Alexandra Glucksmann *et al.*

Serial No.: N/A

Filed: Herewith

For: *14273 RECEPTOR, A NOVEL G-PROTEIN COUPLED RECEPTOR*

Attorney Docket No.: MNI-204CP2DV2

Group Art Unit: 1646

Examiner: Brannock, M.


Commissioner for Patents  
Box Patent Application  
Washington, D.C. 20231

**CERTIFICATION UNDER 37 CFR 1.10**

Date of Deposit: February 13, 2002 Mailing Label Number: EL 892 199 445 US

I hereby certify that this 37 CFR 1.53(b) request and the documents referred to as attached therein are being deposited with the United States Postal Service on the date indicated above in an envelope as "Express Mail Post Office to Addressee" service under 37 CFR 1.10 and addressed to the Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

Larry Taylor  
Name of Person Mailing Paper

  
Signature of Person Mailing Paper

**PRELIMINARY AMENDMENT**

Dear Sir:

Prior to examination of the above-identified application, please amend the application as follows:

In the claims:

Please cancel claims 1-23, without prejudice, and add new claims 24-44 as follows:

24. A method for identifying a compound which modulates a 14273 polypeptide activity, the method comprising:

- a) contacting a cell expressing a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or 4, or a fragment thereof, with a test compound under conditions suitable for modulation of a 14273 polypeptide activity; and
- b) detecting modulation of a 14273 polypeptide activity by the test compound.

25. A method for identifying a compound which modulates a 14273 polypeptide activity, the method comprising:

- a) contacting a cell expressing a polypeptide encoded by the nucleotide sequence contained in the plasmid deposited with ATCC® as Accession Number PTA-1143, or a fragment thereof, with a test compound under conditions suitable for modulation of a 14273 polypeptide activity; and
- b) detecting modulation of a 14273 polypeptide activity by the test compound.

26. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is binding to a G protein in response to ligand binding.

27. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is G protein phosphorylation in response to ligand binding.

28. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is binding to a ligand.

29. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is modulation of intracellular calcium concentration.

30. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is modulation of intracellular cAMP concentration.

31. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is modulation of adenylate cyclase activity.

32. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is modulation of phospholipase C activity.

16462533214273

33. The method of any one of claims 24 or 25, wherein said cell is a cardiac myocyte.

34. The method of any one of claims 24 or 25, wherein modulation of a 14273 polypeptide activity by the test compound is detected by detecting a morphological change in said cell.

35. The method of claim 34, wherein said morphological change is cellular hypertrophy.

36. The method of any one of claims 24 or 25, wherein said test compound is a peptide.

37. The method of any one of claims 24 or 25, wherein said test compound is an antibody.

38. The method of any one of claims 24 or 25, wherein said test compound is a small molecule.

39. The method of any one of claims 24 or 25, wherein said compound stimulates a 14273 polypeptide activity.

40. The method of any one of claims 24 or 25, wherein said compound inhibits a 14273 polypeptide activity.

41. A method for identifying a compound which modulates a 14273 polypeptide activity, the method comprising:

a) contacting a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or 4, or a fragment thereof, with a test compound under conditions suitable for modulation of a 14273 polypeptide activity; and

b) detecting modulation of a 14273 polypeptide activity by the test compound.

42. A method for identifying a compound which modulates a 14273 polypeptide activity, the method comprising:

a) contacting a polypeptide encoded by the nucleotide sequence contained in the plasmid deposited with ATCC® as Accession Number PTA-1143, or a fragment

2010 LEGEND

thereof, with a test compound under conditions suitable for modulation of a 14273 polypeptide activity; and

b) detecting modulation of a 14273 polypeptide activity by the test compound.

43. The method of any one of claims 41 or 42, wherein said 14273 polypeptide activity is binding to a G protein

44. The method of any one of claims 41 or 42, wherein said 14273 polypeptide activity is binding to a ligand.

#### **REMARKS**

Claims 1-23 were pending in the present application. Claims 1-23 have been canceled, without prejudice, and new claims 24-44 have been added. Accordingly, upon entry of the present amendment, claims 24-44 will be pending. For the Examiner's convenience, the currently pending claims are set forth herein in Appendix A.


Support for new claims 24-44 can be found throughout the specification including the claims as originally filed. Specifically, support for these claims may be found at, for example, page 29, line 25, through page 32, line 29.

No new matter has been added. Any amendments to and/or cancellation of the claims should in no way be construed as an acquiescence to any of the Examiner's rejections and was done solely to expedite the prosecution of the application. Applicants reserve the right to pursue the claims as originally filed in this or a separate application(s).

**CONCLUSION**

In view of the amendments and remarks set forth above, it is respectfully submitted that this application is in condition for allowance. If there are any remaining issues or the Examiner believes that a telephone conversation with Applicants' Attorney would be helpful in expediting prosecution of this application, the Examiner is invited to call the undersigned at (617) 227-7400.

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP

  
Maria C. Laccotripe, Ph.D.  
Attorney for Applicant  
Limited Recognition Under 37 C.F.R. §10.9(b)

28 State Street  
Boston, Massachusetts 02109  
telephone: (617) 227-7400  
facsimile: (617) 742-4214  
Date: February 13, 2002

2025 RELEASE UNDER E.O. 14176

**APPENDIX A**

24. A method for identifying a compound which modulates a 14273 polypeptide activity, the method comprising:

- a) contacting a cell expressing a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or 4, or a fragment thereof, with a test compound under conditions suitable for modulation of a 14273 polypeptide activity; and
- b) detecting modulation of a 14273 polypeptide activity by the test compound.

25. A method for identifying a compound which modulates a 14273 polypeptide activity, the method comprising:

- a) contacting a cell expressing a polypeptide encoded by the nucleotide sequence contained in the plasmid deposited with ATCC® as Accession Number PTA-1143, or a fragment thereof, with a test compound under conditions suitable for modulation of a 14273 polypeptide activity; and
- b) detecting modulation of a 14273 polypeptide activity by the test compound.

26. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is binding to a G protein in response to ligand binding.

27. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is G protein phosphorylation in response to ligand binding.

28. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is binding to a ligand.

29. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is modulation of intracellular calcium concentration.

30. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is modulation of intracellular cAMP concentration.

31. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is modulation of adenylate cyclase activity.

32. The method of any one of claims 24 or 25, wherein said 14273 polypeptide activity is modulation of phospholipase C activity.

33. The method of any one of claims 24 or 25, wherein said cell is a cardiac myocyte.

34. The method of any one of claims 24 or 25, wherein modulation of a 14273 polypeptide activity by the test compound is detected by detecting a morphological change in said cell.

35. The method of claim 34, wherein said morphological change is cellular hypertrophy.

36. The method of any one of claims 24 or 25, wherein said test compound is a peptide.

37. The method of any one of claims 24 or 25, wherein said test compound is an antibody.

38. The method of any one of claims 24 or 25, wherein said test compound is a small molecule.

39. The method of any one of claims 24 or 25, wherein said compound stimulates a 14273 polypeptide activity.

40. The method of any one of claims 24 or 25, wherein said compound inhibits a 14273 polypeptide activity.

41. A method for identifying a compound which modulates a 14273 polypeptide activity, the method comprising:

- contacting a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or 4, or a fragment thereof, with a test compound under conditions suitable for modulation of a 14273 polypeptide activity; and
- detecting modulation of a 14273 polypeptide activity by the test compound.

42. A method for identifying a compound which modulates a 14273 polypeptide activity, the method comprising:

- a) contacting a polypeptide encoded by the nucleotide sequence contained in the plasmid deposited with ATCC® as Accession Number PTA-1143, or a fragment thereof, with a test compound under conditions suitable for modulation of a 14273 polypeptide activity; and
- b) detecting modulation of a 14273 polypeptide activity by the test compound.

43. The method of any one of claims 41 or 42, wherein said 14273 polypeptide activity is binding to a G protein

44. The method of any one of claims 41 or 42, wherein said 14273 polypeptide activity is binding to a ligand.

CONFIDENTIAL